Japan approves first RSV vaccine for adults 50-59
LONDON: GSK plc (LSE/NYSE: GSK) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication...
GSK acquires full rights to mRNA candidate vaccines
GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations...
GSK intends to completely offload Haleon shares
LONDON, UK: GSK plc (LSE/NYSE: GSK) it intends to sell approximately 385 million ordinary shares in Haleon, equivalent to approximately 4.2% of Haleon’s issued share...
GSK completes sale of shares in Haleon
LONDON: GSK plc announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc at...
GSK to buy Aiolos Bio for $1.4 billion, boosting its respiratory portfolio
GSK completes acquisition of Aiolos Bio LONDON: GSK plc, a global pharmaceutical company, announced today that it has agreed to acquire Aiolos Bio, Inc., a...
GSK agrees to acquire Sierra Oncology for $1.9bn
LONDON, UK: GlaxoSmithKline plc (LSE: GSK) and Sierra Oncology Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a...
GSK announced positive headline results from five studies
LONDON, UK: GlaxoSmithKline plc announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat,...
GSK sets new environmental goals
LONDON: GSK has announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a...
GSK sells its holding in Hindustan Unilever Limited
LONDON: On 1 April 2020 GlaxoSmithKline plc (GSK) announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to...